Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Chimerix: An Intriguing Near Term and Long Term Outlook for the Stock (CMRX, Buy, $5.67)

Investment Thesis in Brief
I am recommending purchase of Chimerix at the current price. The failure of brincidofovir in the phase…
Read more…

Chimerix: Upgrading the Stock to a Buy (CMRX. Buy, $6.10)

Definitions of Key Words

This section defines a number of words, phrases and acronyms that I have used in this report…
Read more…

Chimerix: An Update (CMRX, $52.83, Neutral)

Company Description

Chimerix is focused on the development and commercialization of antiviral drugs. Its lead product brincidofovir is a phospholipid derivative…
Read more…